TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35241023

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic acid (TXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32521015

Group type: EXPERIMENTAL
Intervention: diacerein 50 mg once daily for 1 month and twice daily thereafter (n=140)
Number of subjects: 380

Group type: COMPARATOR
Intervention: celecoxib 200 mg once daily (n=148)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 380

Group type: COMPARATOR
Intervention: celecoxib
Number of subjects: 380
Study: 36219237

Group type: EXPERIMENTAL
Intervention: DWI_score based on histogram features of multi b‐value DWI functional parameters
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Prognostic model combining DWI_score, TNM-stage, mesorectal fascia (MRF), and extramural venous invasion (EMVI)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Mean value of functional parameters from multi b‐value DWI
Number of subjects: 161
Study: 32299481

Group type: EXPERIMENTAL
Intervention: Self-made combined elastic compression device
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 59
Study: 34489860

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Metformin only (Control)
Number of subjects: 130
Study: 37462593

Group type: EXPERIMENTAL
Intervention: Anatomic complete revascularization (ACR) in INV group
Number of subjects: 4824

Group type: EXPERIMENTAL
Intervention: Functional complete revascularization (FCR) in INV group
Number of subjects: 4824

Group type: EXPERIMENTAL
Intervention: Achieving complete revascularization (CR) in all INV patients
Number of subjects: 4824

Group type: EXPERIMENTAL
Intervention: INV management strategy
Number of subjects: 4824

Group type: COMPARATOR
Intervention: CON management strategy
Number of subjects: 4824
Study: 32640842

Group type: EXPERIMENTAL
Intervention: Ultra rapid lispro (URLi)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Insulin lispro (Humalog®)
Number of subjects: 49
Study: 32978185

Group type: EXPERIMENTAL
Intervention: Critical care telehealth program (daily telemedical rounds at ICU)
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Critical care telehealth program
Number of subjects: 1431
Study: 36714789

Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity (EPA) exercise intervention group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual Physical Activity (UPA) group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Comparison between UPA and EPA groups
Number of subjects: 23
Study: 32495860

Group type: EXPERIMENTAL
Intervention: ERBB2 shRNA group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: ERBB2 overexpression group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Negative control (NC) group
Number of subjects: 240
Study: 36061844

Group type: EXPERIMENTAL
Intervention: Double-bundle ACLR with lateral release (group 3)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-bundle ACLR (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double-bundle ACLR (group 2)
Number of subjects: 100
Study: 33637547

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Neostigmine and Sugammadex
Number of subjects: 60
Study: 33396458

Group type: EXPERIMENTAL
Intervention: Fish-oil (FO) supplementation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) supplementation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: FO + 5-MTHF supplementation
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Higher AA/DHA ratio at delivery
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: FADS1 rs174556 heterozygotes
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Maternal tHcy levels at delivery
Number of subjects: 143
Study: 34931908

Group type: EXPERIMENTAL
Intervention: Peer support group for 10 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: General health reading material for 10 weeks (Control)
Number of subjects: 42
Study: 34702595

Group type: EXPERIMENTAL
Intervention: Simulative heartbeat nest with a heart beating device for 15 minutes
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group observed in the nest without the device for 15 minutes
Number of subjects: 52
Study: 36482468

Group type: EXPERIMENTAL
Intervention: AR-Centre
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: AR-Home
Number of subjects: 129

Group type: COMPARATOR
Intervention: AR-All
Number of subjects: 129
Study: 34552706

Group type: EXPERIMENTAL
Intervention: Intracavitary electrocardiogram (IEGM) guided diagnosis under data mining algorithms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional electrocardiogram (EGM) diagnosis
Number of subjects: 100
Study: 32194219

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-sitagliptin
Number of subjects: 164
Study: 35401769

Group type: EXPERIMENTAL
Intervention: MICT + RT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: HIIT + RT
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 33010241

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Number of subjects: 613

Group type: COMPARATOR
Intervention: Efavirenz 400 mg
Number of subjects: 613
Study: 34294398

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 781
Study: 32932898

Group type: EXPERIMENTAL
Intervention: SRP + ozonated olive oil mouthwash
Number of subjects: 96

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 96
Study: 34118635

Group type: EXPERIMENTAL
Intervention: Psychotropic medication (long-term use)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antidepressants plus lithium (long-term use)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Antipsychotics (long-term use)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Brief psychological therapy (ASSIP) added to medication
Number of subjects: 120

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 120
Study: 32027542

Group type: EXPERIMENTAL
Intervention: Heated-water exercise therapy (HWET) for 12 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Land-based exercise therapy (LBET) for 12 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both HWET and LBET
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Heated-water exercise therapy (HWET)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Land-based exercise therapy (LBET)
Number of subjects: 53
Study: 32956264

Group type: EXPERIMENTAL
Intervention: Mud pack with menthol and Arnica montana (MUD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 33862001

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg tablets twice per day for up to 2 years)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391
Study: 35502234

Group type: EXPERIMENTAL
Intervention: Liposomal drugs for cancer therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Interventional trials
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Phase 3 trials
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Phase 1 trials
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Phase 2 trials
Number of subjects: 74
Study: 32033103

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg/b.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg/b.m.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine (3 and 6 mg/kg/b.m.)
Number of subjects: 12
Study: 34965954

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX/bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFOX/cetuximab
Number of subjects: 0
Study: 33434107

Group type: EXPERIMENTAL
Intervention: Monocyte count 0.60 to <0.95 × 10^9 cells/L
Number of subjects: 2067

Group type: EXPERIMENTAL
Intervention: Monocyte count ≥0.95 × 10^9 cells/L
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Monocyte count <0.60 × 10^9 cells/L
Number of subjects: 2067
Study: 32447638

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB‐EMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 20
Study: 35557386

Group type: EXPERIMENTAL
Intervention: Normal exercise maintenance (EX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Removal of exercise (NOEX)
Number of subjects: 19
Study: 34795281

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) every 4 weeks
Number of subjects: 326

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) every 12 weeks
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: PPQ level of 15.4 ng/mL
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: DP every 4 weeks
Number of subjects: 326
Study: 35726182

Group type: EXPERIMENTAL
Intervention: 5% DMSO
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.3M EDC
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% CHX
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 34579064

Group type: EXPERIMENTAL
Intervention: Krill protein hydrolysate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Soy protein isolate
Number of subjects: 10
Study: 32142961

Group type: EXPERIMENTAL
Intervention: myAirCoach support for 3 to 6 months (study 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: myAirCoach system for 3 months (study 2)
Number of subjects: 42
Study: 35545388

Group type: EXPERIMENTAL
Intervention: Development and Well‐Being Assessment SDA tool as an adjunct to usual clinical care
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 1210
Study: 33594151

Group type: EXPERIMENTAL
Intervention: XP-endo Shaper files
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Kedo-S files
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hand K-files
Number of subjects: 45
Study: 32255580

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hyaluronic acid injections
Number of subjects: 6
Study: 34260693

Group type: EXPERIMENTAL
Intervention: Endoscopic eradication therapy (EET)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Esophagectomy
Number of subjects: 269
Study: 34645661

Group type: EXPERIMENTAL
Intervention: Specialised outpatient treatment in CAG Bipolar
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Generalised community‐based outpatient treatment
Number of subjects: 1000
Study: 32162075

Group type: EXPERIMENTAL
Intervention: GAMBOT intervention delivered through a messaging app for 28 days
Number of subjects: 197

Group type: COMPARATOR
Intervention: Assessments only (control group) for 28 days
Number of subjects: 197
Study: 35306405

Group type: EXPERIMENTAL
Intervention: daridorexant 50 mg
Number of subjects: 28
Study: 35444614

Group type: EXPERIMENTAL
Intervention: Chemotherapy and surgery
Number of subjects: 323

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 323
Study: 32768608

Group type: EXPERIMENTAL
Intervention: A3 test (triple adenylate nucleotides test)
Number of subjects: 400

Group type: COMPARATOR
Intervention: ATP test (adenosine triphosphate test)
Number of subjects: 400
Study: 34218214

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 33208330

Group type: EXPERIMENTAL
Intervention: Semantic treatment for lexical retrieval deficits in the optimal language determined by the BiLex model.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group receiving treatment in the language opposite to the model's recommendation.
Number of subjects: 48
Study: 35587704

Group type: EXPERIMENTAL
Intervention: DLw (deadlifts with lifting straps)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DLn (deadlifts without lifting straps)
Number of subjects: 16

Group type: COMPARATOR
Intervention: DLwn (deadlifts with lifting straps against 80% of DLn 1RM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: DLnn (deadlifts without lifting straps against 80% of DLn 1RM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: DLww (deadlifts with lifting straps against 80% of DLw 1RM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: First repetition as reference
Number of subjects: 16
Study: 34360293

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + unsupervised exercise training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 61
Study: 36377146

Group type: EXPERIMENTAL
Intervention: Sacs left open during herniotomy (experimental group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: High ligation of hernia sac (control group)
Number of subjects: 151
Study: 34182611

Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled doses (0.1–7.7 mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AZD8154 IV infusion (0.15 mg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled doses (0.6, 1.8, and 3.1 mg) with once-daily dosing on Days 4–12
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AZD8154 (all forms)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AZD8154 inhaled route
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: AZD8154
Number of subjects: 78
Study: 34976111

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided laparoscopic technology for postoperative analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional postoperative analgesia methods
Number of subjects: 0
Study: 37173691

Group type: EXPERIMENTAL
Intervention: Facility-based care (FBC) plus community-based rehabilitation (CBR)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Facility-based care (FBC) alone
Number of subjects: 264
Study: 33587007

Group type: EXPERIMENTAL
Intervention: Escape room before simulation
Number of subjects: 233

Group type: COMPARATOR
Intervention: Escape room after simulation
Number of subjects: 233
Study: 34001174

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (1 to 2 units of 200 to 250 ml) along with local standard treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local standard treatment alone
Number of subjects: 100
Study: 33120838

Group type: EXPERIMENTAL
Intervention: Oblique 'Scotty dog' approach (OS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Anteroposterior approach (AP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 36196598

Group type: EXPERIMENTAL
Intervention: T1D with microvascular complications group
Number of subjects: 84
Study: 33905041

Group type: EXPERIMENTAL
Intervention: Vitamin C (0.25 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whey protein (20.0 g) with vitamin C (0.25 g)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (20.0 g of white rice flour) with vitamin C (0.25 g)
Number of subjects: 22
Study: 32728763

Group type: EXPERIMENTAL
Intervention: Breast augmentation with various implant volumes and textures
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Breast projection measurement
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Measurements stability
Number of subjects: 74
Study: 35831692

Group type: EXPERIMENTAL
Intervention: Nomogram based on the log odds of the negative lymph node/T stage ratio (LONT)
Number of subjects: 3895

Group type: EXPERIMENTAL
Intervention: Nomogram risk score
Number of subjects: 3895

Group type: EXPERIMENTAL
Intervention: Low LONT
Number of subjects: 3895
Study: 33734046

Group type: EXPERIMENTAL
Intervention: Dynamic respiratory muscle training
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combined respiratory muscle training
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Static respiratory muscle training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Breathing without applied resistance (Control)
Number of subjects: 53
Study: 33887380

Group type: EXPERIMENTAL
Intervention: Tai chi intervention (2 classes of 60 min duration per week for 10 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 30
Study: 32548849

Group type: EXPERIMENTAL
Intervention: Sodium alginate (Gaviscon Advance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Gaviscon placebo (no alginate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Viscous slurry (saline mixed with sucralose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sodium alginate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32856608

Group type: EXPERIMENTAL
Intervention: Low calcium
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: High calcium
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: High 25(OH)D
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: High calcium and medium 25(OH)D
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Medium calcium and high 25(OH)D
Number of subjects: 1287

Group type: EXPERIMENTAL
Intervention: Other classifications of calcium and serum 25(OH)D levels
Number of subjects: 1287
Study: 35906581

Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavioural therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family-based relaxation therapy
Number of subjects: 0
Study: 32665656

Group type: EXPERIMENTAL
Intervention: Epinephrine group (5 mcg ml-1, n=41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-epinephrine group (n=41)
Number of subjects: 82
Study: 33914286

Group type: EXPERIMENTAL
Intervention: Ponesimod
Number of subjects: 0
Study: 32570252

Group type: EXPERIMENTAL
Intervention: Ustekinumab and briakinumab (combined inhibition of IL-23 and IL-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib (JAK inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib and upadacitinib (JAK inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vedolizumab (α4β7 integrin inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrilumab (α4β7-specific)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etrolizumab (β7-specific)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AJM300 (α4-specific small molecule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-00547659 (antibody against endothelial MadCAM-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozanimod (S1PR1 and S1PR5 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study: 34968730

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg QD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dose-escalated group (initially 15 mg QD, escalated to 30 mg QD if lost response)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Dose-escalated group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Upadacitinib 30 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Upadacitinib 15 mg
Number of subjects: 107
Study: 33857664

Group type: EXPERIMENTAL
Intervention: pvl GPi stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: thalamic stimulation (CM-Voi)
Number of subjects: 10

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: baseline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: long-term follow-up
Number of subjects: 10
Study: 35582938

Group type: EXPERIMENTAL
Intervention: 6-month confirmed disability progression events (score >1.5)
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Sustained progression score based on demographic and clinical characteristics
Number of subjects: 8741

Group type: EXPERIMENTAL
Intervention: Proportions of progression events sustained at 5 years stratified by the score
Number of subjects: 8741
Study: 33640659

Group type: EXPERIMENTAL
Intervention: New graduate physiotherapists' experiences and strategies for managing diagnostic uncertainty
Number of subjects: 17
Study: 32045067

Group type: COMPARATOR
Intervention: Active Monitoring
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 40
Study: 34658136

Group type: EXPERIMENTAL
Intervention: Even Up® Hyperpigmentation Regimen; Colorescience, Inc., Carlsbad, CA
Number of subjects: 33
Study: 33876196

Group type: EXPERIMENTAL
Intervention: Choline (500 mg/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 32216227

Group type: EXPERIMENTAL
Intervention: Tamsulosin, levofloxacin and health education (Group A)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Tamsulosin and health education (Group B)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Health education only (Group C)
Number of subjects: 171
Study: 36302173

Group type: EXPERIMENTAL
Intervention: Cediranib (30 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg)
Number of subjects: 34
Study: 34851253

Group type: EXPERIMENTAL
Intervention: Medicine journals (median impact factor 25.0)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Surgical journals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Surgery publications
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medicine papers
Number of subjects: 20
Study: 33619120

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study: 33239018

Group type: EXPERIMENTAL
Intervention: Cases (received HIV prevention services and enrolled in a 12‐month simulated vaccine efficacy trial using Hepatitis B vaccine)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Controls (received similar health services but did not enroll in SiVET)
Number of subjects: 311